Prostate Cancer News and Research

Latest Prostate Cancer News and Research

GTx fourth quarter net loss increases to $10.7 million

GTx, Inc. today provided a Company update and reported financial results for the fourth quarter and full year 2011.

21 Feb 2012

Genomic instability allows malignant cells to acquire more deadly characteristics

Genomic instability caused by an erosion of the protective caps on chromosomes, followed by activation of an enzyme that reinforces those aps, allows malignant cells to evade destruction and acquire more deadly characteristics, researchers report in an Online Now article at the journal Cell.

21 Feb 2012

AWMSG makes prostate cancer drug abiraterone available on the NHS

Cancer Research UK welcomes the news that the All Wales Medicines Strategy Group (AWMSG) has made prostate cancer drug abiraterone available on the NHS, paving the way for NICE to make a positive ruling when they publish their final guidance in May.

21 Feb 2012

Penn oncologist to discuss role of autophagy in fighting cancer at AAAS annual meeting

Blocking autophagy -- the process of "self-eating" within cells -- is turning out to be a viable way to enhance the effectiveness of a wide variety of cancer treatments.

19 Feb 2012

OICR launches Phase III Active Surveillance Magnetic Resonance Imaging Study Trial

Dr. Nicole Onetto, Deputy Director and Chief Scientific Officer of the Ontario Institute for Cancer Research (OICR), today announced the launch of an innovative Phase III clinical trial that aims to determine whether multi-parametric magnetic resonance imaging (MRI) coupled with transrectal ultrasound (TRUS) guided biopsy (called fusion technology) can accurately identify men with prostate cancer who are at risk of developing aggressive disease.

18 Feb 2012

FDA prioritizes review of Ra-223 and MDV3100 for treating CRPC

The arsenal of prostate cancer treatments for men with advanced prostate cancer may soon be strengthened as the FDA prioritizes the review of both Ra-223 and MDV3100 for treating metastatic castration-resistant prostate cancer (CRPC). Based on positive, independent research of each drug, better survival rates and improved bone health for patients with late-stage prostate cancer may be within reach.

18 Feb 2012

Four new drugs can extend survival and prognosis of prostate cancer

After a decade and a half of near stagnation, four new drugs could help make advanced prostate cancer a chronic illness instead of a terminal disease, a leading Colorado prostate cancer expert says.

17 Feb 2012

IKK2 enzyme plays a key role in proliferation of lung cancer cells

Drugs targeting an enzyme involved in inflammation might offer a new avenue for treating certain lung cancers, according to a new study by scientists at the Salk Institute for Biological Studies.

17 Feb 2012

Hospitals would have to voluntarily return overpayments under new proposal

Even as officials announced record recoveries of fraudulent Medicare claims, they proposed new rules to force providers to voluntarily return overpayments within 60 days of discovering them. The proposal is intended to cut down on the need for criminal or civil investigations.

16 Feb 2012

Combination of photodynamic therapy and software can treat internal tumours

Laser light in combination with certain drugs - known as photodynamic therapy - can destroy cancer tumours, but is today used mostly to cure skin cancer. The reason that internal tumours are not treated with the method is that the technology does not exist to check that the precise amount of light is administered. However, software developed by researchers in atomic physics at Lund University in Sweden looks like being able to solve the problem.

16 Feb 2012

Combination of therapeutic cancer vaccines and chemotherapy shows promise

Therapeutic cancer vaccines, which stimulate the body's immune system to target and destroy cancer cells, are being used in combination with conventional chemotherapy with growing success, as described in several illuminating articles in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc.

16 Feb 2012

Gen-Probe receives FDA approval for PROGENSA PCA3 assay

DiagnoCure, Inc., a Quebec life sciences company that develops and commercializes high‐value cancer diagnostic tests, announced today that the US Food and Drug Administration (FDA) has approved Gen-Probe's PROGENSA PCA3 (Prostate Cancer Antigen 3) assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.

15 Feb 2012

Steady increase in Low Molecular Weight Heparin use for blood clots: Study

The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologist, funded by the National Cancer Institute and led by Kaiser Permanente Colorado.

15 Feb 2012

Aspirin-like drugs help prevent spread of tumors in the body

Australian scientists have made a breakthrough which could help in the fight against cancer. The team from Peter MacCallum Cancer Centre in Melbourne has found a link between non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, and the ability of tumours to spread in the body. They say that doctors have been aware of the benefits of NSAIDs for many years, but did not fully understand the biological processes involved.

14 Feb 2012

Bilateral nerve sparing helps retain orgasmic function after prostrate cancer surgery

The vast majority of men who have a prostate cancer operation can retain their ability to orgasm if the surgery is carried out without removing the nerves that surround the prostate gland like a hammock, according to a study in the February issue of the urology journal BJUI.

14 Feb 2012

Tiltan initiates TL-118 Phase 2 clinical trial for pancreatic cancer

Tiltan Pharma Ltd. today announced that it has commenced a Phase 2 clinical trial of its anti-angiogenic product TL-118 for the treatment of pancreatic cancer.

13 Feb 2012

Curcumin may block growth of castrate-resistant prostate tumors

Curcumin, an active component of the Indian curry spice turmeric, may help slow down tumor growth in castration-resistant prostate cancer patients on androgen deprivation therapy (ADT), a study from researchers at Jefferson's Kimmel Cancer Center suggests.

13 Feb 2012

IKBKE protein plays two roles in tobacco-related NSCLC

Researchers at Moffitt Cancer Center in Tampa, Fla., have discovered that the immune response regulator IKBKE (serine/threonine kinase) plays two roles in tobacco-related non-small cell lung cancers. Tobacco carcinogens induce IKBKE and, in turn, IKBKE induces chemotherapy resistance.

10 Feb 2012

Two new NCCN guidelines for patients with colon and prostrate cancer

In order to provide people with cancer and their caregivers state-of-the-art treatment information in patient-friendly language, the National Comprehensive Cancer Network (NCCN) has developed two new publications: a new release of the NCCN Guidelines for Patients: Colon Cancer and an update to the NCCN Guidelines for Patients: Prostate Cancer.

9 Feb 2012

FDA panel votes against Amgen’s Xgeva in prostate cancer

An FDA panel of oncologists has voted against a new use for Amgen's Xgeva in prostate cancer on Wednesday, saying the drug's ability to slow the spread of the disease did not translate into meaningful benefits for patients. Xgeva is already approved to prevent fractures in cancerous bones, and for osteoporosis, in a different formulation called Prolia.

9 Feb 2012